1	Real world performance of inactivated SARS-CoV-2 vaccine (CoronaVac) against							
2	infection, hospitalization and death due to COVID-19 in adult population in Indonesia							
3								
4	Anton Suryatma ¹ *, Raras Anasi ² , Miko Hananto ² , Asep Hermawan ¹ , Ririn Ramadhany ³ , Irene							
5	Lorinda Indalao ³ , Agustiningsih Agustiningsih ¹ , Ely Hujjatul Fikriyah ² , Kristina Lumban							
6	Tobing ¹ , Teti Tejayanti ² , Rustika Rustika ¹ , Pandji Wibawa Dhewantara ¹ *							
7								
8	¹ National Agency for Research and Innovation, Jl. M.H. Thamrin No. 8, Jakarta 10340,							
9	Indonesia							
10	² Center for Policy on Global Health and Health Technology, Institute of Health Policy							
11	Development, Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560,							
12	Indonesia							
13	³ Center for Policy on Health System and Resources, Institute of Health Policy Development,							
14	Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560, Indonesia							
15								
16 17	*Authors contributed equally							
18	Correspondence: Anton Suryatma, MD, MPH., National Agency for Research and Innovation,							
19	Jl. M.H. Thamrin No. 8, Jakarta 10340, Indonesia. Email: drantonsuryatma@gmail.com							
20								
21								
22 23								
24								
25								
26 27								
27 28								
29								
30								
31								
32								
33 34								
35								
36								
37								
38								
39 40								
41								
42	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.							

43 Abstract

Background: Inactivated SARS-CoV-2 vaccine has been included in the national COVID-19
vaccination program in Indonesia since January 2021. The study aims to assess the impacts of
inactivated COVID-19 vaccine on infection, hospitalization, and death among adult population
aged ≥18 years in Bali, Indonesia.

48 **Methods**: Test-negative, case control study was conducted by linking SARS-CoV-2 laboratory 49 records, vaccination, and health administrative data for the period of January 13 to June 30, 2021. Case-subjects were defined as individuals who had a positive RT-PCR test for SARS-50 51 CoV-2 during the period; they were matched with controls (tested negative) (1:1) based on age, sex, district of residence, and week of testing. We estimated the odds of vaccination in PCR 52 confirmed, hospitalization and death due to COVID-19, accounting for the presence of 53 54 comorbidities and prior infection. Vaccine effectiveness was estimated as (1-odds ratio) x 100%. 55

56 **Results**:

Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021. Of these, 14,168 subjects were eligible for inclusion in the study. Total 5518 matched case-control pairs were analyzed. Adjusted vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 infection was 14.5% (95% confidence interval -11 to 34.2) at 0-13 days after the first dose; 66.7% (95% CI: 58.1- 73.5) at \geq 14 days after the second dose. The adjusted effectiveness against hospitalization and COVID-19-associated death was 71.1% (95% CI: 62.9-77.6) and 87.4% (95% CI: 65.1-95.4%) at \geq 14 days after receiving the second dose, respectively.

64 **Conclusions**: Two-dose of inactivated CoronaVac vaccine showed high effectiveness against

65 laboratory confirmed COVID-19 infection, hospitalization, and death associated with COVID-

66 19 among adults aged \geq 18 years.

67 Keywords: inactivated vaccine, COVID-19, effectiveness, test-negative, Indonesia

68 Introduction

69 Indonesia rolled-out the first phase of mass vaccination program on January 13th, 2021, using the inactivated SARS-CoV-2 vaccine, CoronaVac, manufactured by Sinovac Life Sciences, 70 71 Beijing, China. In the first phase, mass COVID-19 vaccination was targeting healthcare 72 workers and general population including adults and elderly. A phase 1 and 2 clinical trial in 73 China indicated that CoronaVac was tolerable, with acceptable safety and immunogenicity, and 74 therefore supported the conduct of a phase 3 clinical trial in three countries including Indonesia 75 [1]. The efficacy of CoronaVac varied among the countries, ranging from 50.7% to 84% against 76 SARS-CoV-2 infection [2-4]. In Indonesia, two doses of CoronaVac vaccine had an efficacy 77 of 65.3% against COVID-19 illness after 14 days of injection; this supported the approval of emergency use authorization (EUA) by the Indonesia National Agency of Drug and Food 78 Control (NADFC) [2, 5]. 79

Evidence regarding the real-world effectiveness of inactivated CoronaVac vaccine against 80 81 SARS-CoV-2 infection, hospitalization, and death related with COVID-19 have been reported 82 in number of countries such as Chile, Turkey, and Brazil [6, 7]. These studies suggest that the effectiveness of CoronaVac was varied from region to region. Therefore, since the performance 83 in the population found to be different from that reported efficacy under controlled trial 84 circumstances, post-licensure vaccine effectiveness evaluation at the population level is crucial 85 86 [8]. In Indonesia, study on evaluating CoronaVac vaccine performance in preventing COVID-87 19 infection and severe outcomes is still limited especially in adults aged 18 years and above. The objective of this study was to estimate vaccine effectiveness (VE) of inactivated 88 CoronaVac vaccine against COVID-19 infection, hospitalization, and COVID-19-related death 89 90 among adult aged ≥ 18 years in Bali.

91

93 Materials and methods

94 *Setting and design*

Bali is a one of the popular tropical islands in Indonesia, with a total land area of 5780 km² 95 and population of more than 4.3 million [9]. Mass COVID-19 vaccination using inactivated 96 SARS-CoV-2 (CoronaVac) was initiated by the Ministry of Health of Indonesia on January 97 13, 2021, across Indonesia, including in Bali. As of July 31, 2021, COVID-19 vaccines have 98 99 been given to 2.8 million (41.9%) of the targeted Balinese population. About 2.2 million 100 people aged ≥ 18 years had received at least one dose of COVID-19 vaccines (Supplementary 101 Figure S1): 1.2 million (43.1%) had received at least one dose of inactivated CoronaVac 102 vaccine [10]. The observation was conducted during January 13 to June 30, 2021. During 103 the study period, the incidence of COVID-19 was increased during January-February and 104 followed with a declining trend from March to June 2021. There was a sharp increase in 105 incidence in July due to B.1.617.2 (Delta) variants (Figure 2, Supplementary Figure S2).

106 We conducted a record-based retrospective, test-negative, matched case control (1:1) study 107 to evaluate the effectiveness of inactivated CoronaVac vaccine in preventing laboratory 108 confirmed SARS-CoV-2 infection, among adults (aged ≥18 years) during January to June 109 2021. This test negative design was chosen due to several reasons. First, accessibility to 110 individual data who were laboratory-tested for SARS-CoV-2 was feasible through the 111 national surveillance system; second, it was cost-effective and allowed for faster results; and 112 lastly, the design could better control for potential biases, including healthcare seeking 113 behavior and access to COVID-19 testing [11].

114

115 Data sources

We linked individual health electronic databases including SARS-CoV-2 reverse-transcription
polymerase chain reaction (RT-PCR) test results from the national laboratory testing database

(New All Record), COVID-19 vaccination registry, and hospitalization claims, managed by the Ministry of Health of Indonesia, using unique national citizen identification number. Data with foreign identification number and driving license number were excluded. We also checked the consistency in identification number, name, date of birth and sex between these databases. Confirmatory SARS-CoV-2 PCR test was performed on naso and/or oropharyngeal swab specimens in COVID-19 reference laboratories.[12]

- 124
- 125 Selection of cases and matched controls

126 Cases were adults aged ≥18 years identified as those who had at least one COVID-19-like 127 symptom (fever with body temperature documented at \geq 38°C, chills, cough, shortness of 128 breath. fatigue or malaise, sore throat, headache, runny nose, congestion, muscle aches, nausea 129 or vomiting, diarrhea, abdominal pain, altered sense of smell or taste) and were tested RT-PCR 130 positive for SARS-CoV-2, between January 13 to June 30, 2021; were not confirmed as positive 131 for SARS-CoV-2 in the last 90 days before the index date; and those who did not receive any 132 COVID-19 vaccines other than CoronaVac before sample collection. Controls were defined as 133 those who had negative RT-PCR test results during the same period, irrespective for symptoms; 134 and who did not receive any COVID-19 vaccines other than CoronaVac before sample 135 collection. Cases and control were matched based on age, sex, district of residence and week of 136 sample collection/testing.

137

138 *Vaccination status*

Vaccination status of the subjects was determined by referring to linked individual vaccination record and was determined based on their SARS-CoV-2 test date. Fully vaccinated cases and controls were defined as having two doses of CoronaVac at least 14 days before the sample collection date. Adults who received no single dose of CoronaVac vaccine were defined as

unvaccinated and all other adults who received one dose at least 14 days before samplecollection date were defined as partially vaccinated.

145

146 Statistical analysis

Unadjusted and adjusted odds of vaccination between test-positive and test-negative pairs were 147 148 estimated using conditional logistic regression. Odds ratios (ORs) and 95% confidence interval 149 (CI) of vaccination in cases and controls was compared. Adjusted ORs were estimated from 150 models including age (by year, as continuous) and presence of comorbidities and prior SARS-151 CoV-2 infection. There was a considerable proportion of missing data for comorbidities (79%). 152 Multiple imputation was performed with considering for covariates (age, sex, residence) and 153 outcome. Vaccine effectiveness (VE) was calculated as (1-OR) x 100% and 95% CIs for 154 vaccine effectiveness estimates as $100 \times (1$ -upper or lower bounds of 95% CI for adjusted OR 155 [13].

156 The effectiveness of CoronaVac against secondary outcomes (hospitalization and death due to 157 COVID-19) were estimated using a multivariable logistic regression, accounting for covariates 158 such as age, sex, district of residence, imputed presence of comorbidities and week of sample 159 collection. Subgroup analyses were also performed to assess VE based on the age group.

Sensitivity analysis was conducted on an unmatched population using a multivariable logistic regression model, adjusted for age, sex, district of residence, presence of comorbidities and week of testing. Statistical significance was set at p-value < 0.05. All statistical analyses were conducted using STATA software version 15.0 (Stata Cooperation, College Station, Texas, USA).

165

166

168 **Results**

169 *Study population*

Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021 170 171 (Figure 1). Of which, 14,168 subjects were eligible for inclusion in the study. Of these, 2886 172 (20.4%) were tested positive for SARS-CoV-2 and 11,282 (79.6%) tested negative for SARS-173 CoV-2 infection. Of these, 5518 (39%) matched case-control pairs were eligible for analysis 174 after matching by age, sex, geography (district of residence), and week of testing. 175 The characteristics of the study population and matched case-control pairs were presented in 176 Table 1. The median age of the overall study sample (n=14,168) was 50 years (interquartile range, 31-65 years); 50.8% were aged \geq 50 years. Thirty percent (n=4259) resided in Denpasar 177 178 city. Thirty four percent (n=4863) had received full vaccination; 42.5% (n=6016) had not

- received vaccine. Those who receiving positive RT-PCR test results were appeared much older,males, had at least one comorbidity and unvaccinated.
- Among the case subjects, about 40% of subjects having comorbidities. Based on vaccination status, 16,4% (n=453) had received two doses of CoronaVac vaccine. Nineteen percent (n=535) case subjects had received the first dose of CoronaVac vaccine and about two-third (n=1771) were unvaccinated. While among participants in the control group, half of the participants (n=1485/2759) were unvaccinated. Twenty four percent had received two doses of CoronaVac vaccine.
- 187

188 *Vaccine effectiveness*

The unadjusted effectiveness of two doses of CoronaVac in preventing laboratory confirmed
SARS-CoV-2 at least 14 days after administration was 73% (95% CI: 67-78) (Table 2). After
adjusting for covariates, compared to unvaccinated adults, two dose of CoronaVac improved
protection against SARS-CoV-2 infection (VE: 66.7%; 95% CI: 58.1-73.5) at ≥14 days after

193 the second dose. Partial vaccination with CoronaVac was not significantly associated with a 194 reduced risk of laboratory-confirmed SARS-CoV-2 infection (VE: 14.5%; 95% CI: -11 to 34.2) 195 at 0-13 days after the first dose. The effectiveness of CoronaVac vaccine against COVID-19 196 infection was reduced with increasing age. 197 The adjusted VE in preventing COVID-19-related hospitalization and death was 71.1% (95% 198 CI: 62.9-77.6) and 87.4% (95% CI: 65.1-95.4), respectively, at 14 days after the second dose 199 (Table 3). Partial vaccination was less protective against COVID-19-related hospitalization and 200 death among people aged 18 and older. Vaccine effectiveness against hospitalization was higher 201 79.4% (95% CI: 70-85.9) in group of people aged \geq 50 years relative to people aged 18-49 years 202 (65.8%; 95% CI: 49.1-77). Death due to COVID-19 was not significantly associated with full 203 vaccination in people aged 18-49 years (VE: 65.7%, 95% CI: -99.5 to 94.1). This result could 204 be happened due to an effect of small sample size and small number of events (mortality). 205 Among older population, vaccine effectiveness was 90.6% (95% CI:61.5-97.7) in preventing 206 death due to COVID-19.

To address potential issues related to the small sample size and rare event or outcome, we conducted a sensitivity analysis using unmatched population (n=14,168) (Supplementary Table S1 - Table S3). Overall, after adjusting all covariates, the vaccine effectiveness was 66.7% (95%CI: 61-71.5) in preventing laboratory confirmed SARS-CoV-2 infection at 14 days or more after the second dose administration. The effectiveness was relatively higher in adults aged 18-49 years (VE: 76.9; 95%CI: 77.3-86.6) compared to that older participants (VE: 69.4%, 95%CI: 60.8-76.2), at 14 days after the second dose.

The effectiveness against hospitalization and death related to COVID-19 was 77.7% (95%CI: 73.2-81.5) and 93.9% (95%CI: 85-97.6%), respectively, at 14 days after second dose. The effectiveness against both hospitalization and death due to COVID-19 was higher in that

population aged 50 years or older (82.6% and 94.4%, respectively) compared to group of people
aged 18-49 years (71.8% and 88.1%, respectively).

219

220 Discussion

High proportion of inactivated vaccine of CoronaVac have been used in national COVID-19 221 222 vaccination program in Indonesia. So far, this is the first health record-based observational 223 study that provide real-world evidence on the effectiveness of COVID-19 vaccine against laboratory-confirmed SARS-CoV-2 infection, hospitalization, and death in Indonesian 224 225 population. The study showed complete regimen of CoronaVac vaccine at least 14 days after 226 the second dose had an effectiveness of 66.7% (95% CI: 58.1-73.5) against COVID-19 infection 227 among Balinese adults aged ≥ 18 years. This finding is consistent with the results of phase III 228 trial [5]. Yet, the effectiveness against infection was reduced by age. The effectiveness against 229 infection was slightly lower in elderly aged 50 years and above (69.9%; 95% CI: 57.7-78.7) 230 compared to younger adults (18-49 years) (77%, 95% CI: 66.6-84.2). This could be associated with the difference in immune response. It has been observed in older people that the antibody 231 232 titre was rapidly degraded, the immune response was delay and the peak of neutralizing 233 antibodies was relatively lower than younger populations [14]. These findings highlight the 234 necessity for elderly-specific immunization approaches (e.g., vaccine formulations and 235 administration).

Our real-world evidence on the effectiveness of CoronaVac against laboratory confirmed SARS-CoV-2 infection was consistent with that randomized controlled trials of vaccine efficacy in Indonesia (65.3%; 95%CI: 20-85.1) [2]. Yet, it was lower than that of vaccine efficacy reported in Turkey (83.5%; 95% CI: 65.4-92.1) and higher than that efficacy reported from Brazil (51%; 95%CI: 36-62) at 14 days after the second vaccination [3, 15]. Chilean cohort VE study involving general population aged \geq 16 years old also demonstrated the VE was 65.9%

242 (95% CI: 65.2%-66.6%) against COVID-19 infection. While a TND case control study in Brazil 243 demonstrated that two dose regimens of CoronaVac was effective in reducing risk of 244 symptomatic COVID-19 (46.8%; 95%CI: 38.7% to 53.8%) at \geq 14 days after the second dose 245 among older population aged \geq 70 years [7]. Another inactivated vaccine platform, BBV152 (a whole-virion inactivated vaccine manufactured by Bharat Biotech, Covaxin) which is used in 246 247 India, has also been reported to be effective against COVID-19. A study reported that the 248 effectiveness of against symptomatic COVID-19 was 50% (95% CI: 33-62) [16]. Compared to 249 the effectiveness of CoronaVac vaccine, BBV152 effectiveness is slightly lower. The difference 250 in the amount of transmission and the circulating SARS-CoV-2 variant are likely to have an 251 impact on the results.

Our study showed that full vaccination of CoronaVac vaccine was also effective in preventing 252 hospitalization and COVID-19-associated death. We estimated that CoronaVac vaccine was 253 254 71.1% (95% CI: 62.9-77.6) for the prevention of hospitalization and 87.4% (95% CI: 65.1-95.4) 255 for the prevention of COVID-19-related death at least 14 days after the second dose. While 256 partial vaccination provided less protection against hospitalization and death due to COVID-257 19. None has reported CoronaVac VE estimates against these two outcomes in Indonesia. Our 258 estimates, however, are dissimilar to that estimate reported elsewhere. A cohort study in Chile among adults aged ≥ 16 years showed that CoronaVac vaccine was 87.5% (95% CI, 86.7-88.2) 259 effective against hospitalization and 86.3% (95% CI, 84.5-87.9) effective against COVID-19-260 related death [6, 17]. While a TND study in Brazil among elderly aged 70 years or older, 261 262 CoronaVac was effective against COVID-19-related hospitalization (55.5%; 95%CI: 46.5-263 62.9) and death (61.2%, 95% CI: 48.9-70.5) at \geq 14 days after the second dose, respectively [7]. A study on another inactivated vaccine showed that the effectiveness of full vaccination of 264 265 Sinopharm BBIBP-CorV was 79.8% (95% CI: 78–81.4) in preventing hospital admission and 97.1% (83–99.9) in preventing death among Abu Dhabi residents aged 15 years and older [18]; 266

which is slightly higher than our estimates on the effectiveness of CoronaVac. This discrepancy
might be due to several factors including variation in study population and design (e.g., targeted
age group, sample size) and difference in level of transmission or epidemiological setting (e.g.,

a TND study in Brazil was conducted when P.1 or Gamma variant was predominant).

271 Our adjusted effectiveness

272 The strengths of this study are that: i) we used comprehensive health administrative database 273 including individual laboratory test results, vaccination data and hospitalizations which include 274 information on date of sample collection, type of vaccine, date of vaccination, date of hospital 275 admission and underlying conditions; (ii) the subjects were chosen based on a standard 276 laboratory confirmation for SARS-CoV-2 results. Thus, biases due to misclassification from 277 infection or vaccination status were implausible. These findings are important to fill the gap in 278 our knowledge regarding the performance of inactivated CoronaVac vaccine in the real-world; 279 (iii) our analysis have sufficient of power (99.3%) as our matched case-control study involved 280 large number of samples (2759 cases) with known vaccine effectiveness of 65% against 281 symptomatic SARS-CoV-2 \geq 14 days after the second dose.

282 However, our study has limitations. First, while we attempted to make a robust approach by 283 adjusting for number of potential confounding factors, including age, sex, geography, week of 284 testing (sample collection) and presence of comorbidities, there might be still unmeasured 285 confounding factors that biased the VE estimates (e.g., behavioral risk factors, type of variants). 286 Second, we did not have a detailed information on symptoms and date of onset in the record so 287 that we could not identified and specifically examine the effectiveness against symptomatic 288 cases. Third, as the data for date on onset were not available in the records, we used date of 289 sample collection instead. There might be false-negative results included in the study so that 290 this could affect our estimate. Lastly, this study was retrieved data from January to June 2021, 291 which was just before the peak of Delta variants (B.1.617.2) outbreaks. Hence, the VE estimates

292	presented here is likely reflected vaccine performance before Delta and Omicron becoming
293	predominant variant in the community. VE of CoronaVac against Delta and Omicron-related
294	infection and severity might be different. Studies elsewhere have reported the effects of Delta
295	variants on the COVID-19 vaccines performance [19, 20]. Further research is required to
296	evaluate the effectiveness of CoronaVac against the circulating VOCs.
297	
298	Conclusions
299	The two-dose regimens of inactivated CoronaVac vaccine was effective in preventing COVID-
300	19 infection, hospitalizations for COVID-19 and COVID-19-related death in adults aged 18
301	years or older. Full vaccination was significantly reduced the risk of severe outcomes especially
302	among 50 years or older.
303	
304	Author contributions
305	Study conceptualization: AS, PWD, RR (Ririn Ramadhany), MH. Methodology: AS, RR (Ririn
306	Ramadhany), MH, PWD. Formal analysis: AS, RA, EHF, PWD, MH. Project administration:
307	RA, RR (Rustika Rustika), KLT, TT. Data collection: AS, RA, EHF, AA, ILI, PWD.
308	Supervision: PWD, RR (Ririn Ramadhany). Validation: PWD, RR (Rustika Rustika), KLT, TT.
309	Funding: AS, TT, MH. Writing (original draft): AS, PWD. Writing (review and editing): all
310	authors. All authors have read and approved the manuscript.
311	
312	Ethic statement
313	The protocol of the study was approved by the Health Research Ethics Committee, National
314	Institute of Health Research and Development, Ministry of Health, Indonesia (LB.
315	02.01/2/KE.533/2021). The study was considered exempt from informed consent. No human
316	health risks were identified.
317	

318 Conflict of interest

The authors declare that they have no competing interests. None of us received shares or any kind monetary compensation linked to the distribution of CoronaVac in Indonesia or have any share or financial interests in Sinovac Life Sciences or parent companies.

322

323 Data availability statement

The datasets used and/or analyzed during the current study are protected by the Ministry of Health of Indonesia and are unsuitable for public sharing. Interested parties can apply for the data by contacting the data center of the Ministry of Health of Indonesia. All data generated or analyzed during this study are included in this published article (and its Supplementary information files). Aggregate data on vaccination and COVID-19 incidence are publicly available at https://vaksin.kemkes.go.id/#/vaccines

330

331 Funding

This study was funded by the National Institute of Health Research and Development, Ministry of Health, Indonesia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the authors and not necessarily those of the Ministry of Health of Indonesia.

336

337 Acknowledgment

We would like to thank Dr. Anas Ma'ruf and team at the Center of Health Data and Information of Ministry of Health Indonesia, and Mr. Made Darmawan and Mr. Akbar Antony Siregar at the National COVID-19 Control and Economic Recovery Committee (KPC-PEN) for their assistance and support in collating the data. We would also like to thank the Ketut Suarjaya and

- 342 I Wayan Widia at Bali Provincial Health Office for their support in the implementation of this
- 343 study and permission to access COVID-19 surveillance data.
- 344

345

346 **References**

- Y. Zhang, G. Zeng, H. Pan, C. Li, Y. Hu, K. Chu, W. Han, Z. Chen, R. Tang, W. Yin, X.
 Chen, Y. Hu, X. Liu, C. Jiang, J. Li, M. Yang, Y. Song, X. Wang, Q. Gao, and F. Zhu,
 "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy
 adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2
 clinical trial," *Lancet Infect Dis*, vol. 21, no. 2, pp. 181-192, 2021.
- Indonesia National Agency of Drug and Food Control, "Emergency Use Authorization CoronaVac," Indonesia National Agency of Drug and Food Control Jakarta, 2021.
- M. D. Tanriover, H. L. Doğanay, M. Akova, H. R. Güner, A. Azap, S. Akhan, Ş. Köse, F.
 Ş. Erdinç, E. H. Akalın, Ö. F. Tabak, H. Pullukçu, Ö. Batum, S. Şimşek Yavuz, Ö. Turhan,
 M. T. Yıldırmak, İ. Köksal, Y. Taşova, V. Korten, G. Yılmaz, M. K. Çelen, S. Altın, İ. Çelik,
 Y. Bayındır, İ. Karaoğlan, A. Yılmaz, A. Özkul, H. Gür, S. Unal, and G. CoronaVac Study,
 "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac):
 interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey,"
 Lancet (London, England), vol. 398, no. 10296, pp. 213-222, 2021.
- R. Palacios, E. G. Patiño, R. de Oliveira Piorelli, M. T. R. P. Conde, A. P. Batista, G. Zeng,
 Q. Xin, E. G. Kallas, J. Flores, C. F. Ockenhouse, and C. Gast, "Double-Blind,
 Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and
 Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated)
 Vaccine Manufactured by Sinovac PROFISCOV: A structured summary of a study
 protocol for a randomised controlled trial," *Trials*, vol. 21, no. 1, pp. 853-853, 2020.
- E. Fadlyana, K. Rusmil, R. Tarigan, A. R. Rahmadi, S. Prodjosoewojo, Y. Sofiatin, C. V.
 Khrisna, R. M. Sari, L. Setyaningsih, F. Surachman, N. S. Bachtiar, H. Sukandar, I.
 Megantara, C. Murad, K. N. A. Pangesti, V. Setiawaty, S. Sudigdoadi, Y. Hu, Q. Gao, and
 C. B. Kartasasmita, "A phase III, observer-blind, randomized, placebo-controlled study of
 the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy
 adults aged 18-59 years: An interim analysis in Indonesia," *Vaccine*, vol. 39, no. 44, pp.
 6520-6528, 2021.
- 374 6. Ministerio de Salud Gobierno de Chile, "Effectiveness of the inactivated CoronaVac
 375 vaccine against SARS-CoV-2 in Chile Preliminary report," Misterio de Salud, Chile, 2021.
- O. T. Ranzani, M. D. T. Hitchings, M. Dorion, T. L. D'Agostini, R. C. de Paula, O. F. P. de
 Paula, E. F. M. Villela, M. S. S. Torres, S. B. de Oliveira, W. Schulz, M. Almiron, R. Said,

- 378 R. D. de Oliveira, P. Vieira da Silva, W. N. de Araújo, J. C. Gorinchteyn, J. R. Andrews,
- D. A. T. Cummings, A. I. Ko, and J. Croda, "Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study," *Bmj*, vol. 374, pp. n2015, 2021.
- 382 8. G. Hanquet, M. Valenciano, F. Simondon, and A. Moren, "Vaccine effects and impact of
 383 vaccination programmes in post-licensure studies," *Vaccine,* vol. 31, no. 48, pp. 5634-42,
 384 2013.
- 9. Provincial Bureau of Statistics of Bali, *Bali in Figure 2021,* Provincial Bureau of Statistics
 of Bali, Denpasar, 2021.
- 387 10. Ministry of Health of Indonesia, "COVID-19 Vaccine Dashboard," Ministry of Health of
 388 Indonesia,,https://vaksin.kemkes.go.id/#/vaccines.
- M. K. Patel, I. Bergeri, J. S. Bresee, B. J. Cowling, N. S. Crowcroft, K. Fahmy, S. Hirve,
 G. Kang, M. A. Katz, C. F. Lanata, M. L'Azou Jackson, S. Joshi, M. Lipsitch, J. M. Mwenda,
 F. Nogareda, W. A. Orenstein, J. R. Ortiz, R. Pebody, S. J. Schrag, P. G. Smith, P.
 Srikantiah, L. Subissi, M. Valenciano, D. W. Vaughn, J. R. Verani, A. Wilder-Smith, and
 D. R. Feikin, "Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary
 of interim guidance of the World Health Organization," *Vaccine*, vol. 39, no. 30, pp. 40134024, 2021.
- 396 12. Ministry of Health of Indonesia, *Guidelines on COVID-19 Prevention and Control, 5th* 397 *revision* Ministry of Health of Indonesia, Jakarta, 2020.
- W. A. Orenstein, R. H. Bernier, T. J. Dondero, A. R. Hinman, J. S. Marks, K. J. Bart, and
 B. Sirotkin, "Field evaluation of vaccine efficacy," *Bulletin of the World Health Organization,* vol. 63, no. 6, pp. 1055-1068, 1985.
- 401 14. D. A. Collier, I. Ferreira, P. Kotagiri, R. P. Datir, E. Y. Lim, E. Touizer, B. Meng, A.
 402 Abdullahi, A. Elmer, N. Kingston, B. Graves, E. Le Gresley, D. Caputo, L. Bergamaschi,
 403 K. G. C. Smith, J. R. Bradley, L. Ceron-Gutierrez, P. Cortes-Acevedo, G. Barcenas404 Morales, M. A. Linterman, L. E. McCoy, C. Davis, E. Thomson, P. A. Lyons, E. McKinney,
 405 R. Doffinger, M. Wills, and R. K. Gupta, "Age-related immune response heterogeneity to
 406 SARS-CoV-2 vaccine BNT162b2," *Nature*, vol. 596, no. 7872, pp. 417-422, 2021.
- 407 15. World Health Organization, Interim recommendations for use of the inactivated COVID-19
 408 vaccine, CoronaVac, developed by Sinovac (Interim Guidance 24 May 2021), World
 409 Health Organization, Geneva, 2021.
- D. Desai, A. R. Khan, M. Soneja, A. Mittal, S. Naik, P. Kodan, A. Mandal, G. T. Maher, R.
 Kumar, A. Agarwal, N. R. Gowda, V. H, P. Kumar, S. Pandey, R. M. Pandey, A. Kumar,
 A. Ray, P. Jorwal, N. Nischal, A. Choudhary, M. Brijwal, K. Madan, R. Lodha, S. Sinha, L.
 Dar, N. Wig, and R. Guleria, "Effectiveness of an inactivated virus-based SARS-CoV-2

414 vaccine, BBV152, in India: a test-negative, case-control study," *The Lancet Infectious*415 *Diseases,* vol. 22, no. 3, pp. 349-356, 2022.

- 416 17. A. Jara, E. A. Undurraga, C. González, F. Paredes, T. Fontecilla, G. Jara, A. Pizarro, J.
 417 Acevedo, K. Leo, F. Leon, C. Sans, P. Leighton, P. Suárez, H. García-Escorza, and R.
 418 Araos, "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile," *New England*419 *Journal of Medicine*, vol. 385, no. 10, pp. 875-884, 2021.
- 18. F. Ismail AlHosani, A. Eduardo Stanciole, B. Aden, A. Timoshkin, O. Najim, W. Abbas
 Zaher, F. AlSayedsaleh AlDhaheri, S. Al Mazrouie, T. A. Rizvi, and F. Mustafa, "Impact of
 the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in
 infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United
 Arab Emirates (UAE)," *Vaccine*, pp. S0264-410X(22)00174-8, 2022.
- J. Lopez Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe,
 E. Tessier, N. Groves, G. Dabrera, R. Myers, C. N. J. Campbell, G. Amirthalingam, M.
 Edmunds, M. Zambon, K. E. Brown, S. Hopkins, M. Chand, and M. Ramsay,
 "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant," *The New England journal of medicine*, vol. 385, no. 7, pp. 585-594, 2021.
- 20. X.-N. Li, Y. Huang, W. Wang, Q.-L. Jing, C.-H. Zhang, P.-Z. Qin, W.-J. Guan, L. Gan, Y.L. Li, W.-H. Liu, H. Dong, Y.-T. Miao, S.-J. Fan, Z.-B. Zhang, D.-M. Zhang, and N.-S.
 Zhong, "Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant
 infection in Guangzhou: a test-negative case-control real-world study," *Emerging microbes & infections,* vol. 10, no. 1, pp. 1751-1759, 2021.

1 **Table and Figure Legends**

3 **Table 1.** Characteristics of the adults aged ≥ 18 years eligible in the study and case-control 4 pairs included in the analysis

5 6 Table 2. CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2 7 infection in adults aged ≥ 18 years in Bali, Indonesia, all age and stratified by age group

8 9 Table 3. CoronaVac vaccine effectiveness in preventing hospitalization and COVID-19-10 related death in adults aged ≥ 18 years in Bali, Indonesia, all ages and stratified by age group 11

12

14

- 13 Figure 1. Flowchart for case and control selection
- Figure 2. Trends in COVID-19 incidence in Bali over the period of study (Data source: 15
- 16 Ministry of Health of Indonesia).



Figure 1. Flowchart for case and control selection





Figure 2. Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry of Health of Indonesia).

Table 1. Characteristics of the adults aged ≥ 18 years eligible in the study and case-control

pairs included in the analysis

Characteristics	Total	Eligible stud	y population	Matched pairs		
		Positive	Negative	Cases	Controls	
		SARS-CoV-2	SARS-CoV-2	(n=2759)	(n=2759)	
		(n=2886)	(n=11,282)			
Age, years, median (IQR)	50 (31-65)	61 (45-69)	46 (30-64)	61 (45-69)	60 (41-70)	
Age group, n (%)						
18-49 у	6969 (49.2)	853 (29.6)	6116 (54.2)	847 (30.7)	847 (30.7)	
≥50 y	7199 (50.8)	2033 (70.4)	5166 (45.8)	1912 (69.3)	1912 (69.3)	
Sex						
Male	7676 (54.2)	1730 (59.9)	5946 (52.7)	1648 (59.7)	1648 (59.7)	
Female	6492 (45.8)	1156 (40.1)	5336 (47.3)	1111 (40.3)	1111 (40.3)	
District of residence, n (%)						
Jembrana	564 (4)	87 (3)	477 (4.2)	75 (2.7)	75 (2.7)	
Tabanan	1500 (10.6)	233 (8.1)	1267 (11.2)	233 (8.5)	233 (8.5)	
Badung	2031 (14.3)	474 (16.4)	1557 (13.8)	465 (16.7)	456 (16.7)	
Gianyar	1573 (11.1)	408 (14.1)	1165 (10.3)	363 (13.2)	363 (13.2)	
Klungkung	554 (3.9)	79 (2.7)	475 (4.2)	73 (2.7)	73 (2.7)	
Bangli	803 (5.7)	222 (7.7)	581 (5.2)	202 (7.3)	202 (7.3)	
Karangasem	916 (6.5)	144 (5)	772 (6.8)	138 (5)	138 (5)	
Buleleng	1968 (13.9)	353 (12.2)	1615 (14.3)	343 (12.4)	343 (12.4)	
Denpasar	4259 (30.1)	886 (30.7)	3373 (29.9)	867 (31.4)	867 (31.4)	
Reported No. of comorbidities,						
n (%)						
No	12,158 (85.8)	1698 (58.8)	10,460 (92.7)	1636 (59.3)	2473 (89.6)	
Yes	2010 (14.2)	1188 (41.2)	822 (7.3)	1123 (40.7)	286 (10.4)	
Vaccination status, n (%)						
Unvaccinated	6016 (42.5)	1867 (64.7)	4149 (36.8)	1771 (64.2)	1469 (53.3)	
1st dose (0-13 days)	1001 (7.1)	222 (7.7)	779 (6.9)	216 (7.8)	193 (7)	
1st dose (≥14 days)	1408 (9.9)	340 (11.8)	1068 (9.5)	319 (11.6)	272 (9.9)	
2nd dose (0-13 days)	880 (6.2)	77 (2.7)	803 (7.1)	74 (2.7)	158 (5.7)	
2nd dose (≥14 days)	4863 (34.3)	380 (13.2)	4483 (39.7)	379 (13.7)	667 (24.2)	

Table 2. CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection in adults aged ≥18 years in Bali, Indonesia,
 all age and stratified by age group

	Cases (SARS-CoV-2 RT-PCR-	Controls (SARS-CoV-2 RT-PCR-	Unadjusted OR (95% CI)	Unadjusted p-value	Adjusted OR* (95% CI)	Adjusted p-value	Adjusted VE (95% CI)
	positive)	negative)					
Unvaccinated	1771 (64.2)	1469 (53.3)	Ref		Ref		
0-13 days after 1 st dose	216 (7.8)	193 (7)	0.77 (0.61-0.98)	0.03	0.85 (0.66-1.11)	0.239	14.5 (-11 – 34.2)
≥ 14 days after 1 st dose	319 (11.6)	272 (9.9)	0.76 (0.62-0.93)	0.007	0.89 (0.71-1.12)	0.332	10.5 (-12 - 28.6)
0-13 days after 2 nd dose	74 (2.7)	158 (5.7)	0.33 (0.24-0.45)	< 0.0001	0.37 (0.26-0.52)	< 0.0001	63.1 (48.5-73.6)
\geq 14 days after 2 nd dose	379 (13.7)	667 (24.2)	0.27 (0.22-0.33)	< 0.0001	0.33 (0.26-0.42)	< 0.0001	66.7 (58.1-73.5)
Age group: 18-49 years							
Unvaccinated	247 (29.2)	95 (11.2)	Ref		Ref		
0-13 days after 1 st dose	133 (15.7)	122 (14.4)	0.43 (0.29-0.62)	< 0.0001	0.52 (0.35-0.77)	< 0.0001	48.3 (22.6-65.5)
\geq 14 days after 1 st dose	144 (17)	131 (15.5)	0.34 (0.23-0.51)	< 0.0001	0.45 (0.30-0.68)	< 0.0001	55.1 (32-70.4)
0-13 days after 2 nd dose	39 (4.6)	79 (9.3)	0.20 (0.12-0.32)	< 0.0001	0.22 (0.13-0.36)	< 0.0001	78.2 (63.6-87)
\geq 14 days after 2 nd dose	284 (33.5)	420 (49.6)	0.18 (0.12-0.25)	< 0.0001	0.23 (0.16-0.33)	< 0.0001	77 (66.6-84.2)
Age group: ≥50 years							
Unvaccinated	1524 (79.7)	1374 (71.9)	Ref		Ref		
0-13 days after 1 st dose	83 (4.3)	71 (3.7)	1.05 (0.75-1.47)	0.775	1.11 (0.74-1.64)	0.617	-10.6 (-64.3-25.5)
\geq 14 days after 1 st dose	175 (9.2)	141 (7.4)	1.02 (0.80-1.30)	0.874	1.13 (0.85-1.51)	0.396	-13.2 (-50.6 - 14.9)
0-13 days after 2 nd dose	35 (1.8)	79 (4.1)	0.38 (0.25-0.58)	< 0.0001	0.42 (0.26-0.68)	< 0.0001	58.1 (32.4-74)
\geq 14 days after 2 nd dose	95 (4.9)	247 (12.9)	0.26 (0.19-0.35)	< 0.0001	0.30 (0.21-0.42)	< 0.0001	69.9 (57.7-78.7)

79 Abbreviations: OR, odds ratio; VE, vaccine effectiveness

80 *Adjusted for age (as continuous), presence of comorbidities and prior SARS-CoV-2 infection

81 [†]Vaccine effectiveness is calculated as (1- odds ratio) x 100%

87 Table 3. CoronaVac vaccine effectiveness in preventing hospitalization and COVID-19-related death in adults aged ≥18 years in Bali,
88 Indonesia, all ages and stratified by age group

	Hospitalization				Death due to COVID-19			
		Adjusted OR	Adjusted	VE*	n/N	Adjusted OR	Adjusted	VE*
	n/N	(95% CI)	p-value	% (95%CI)		(95% CI)	p-value	% (95%CI)
Unvaccinated	1932/3240	Ref			450/3240	Ref		
0-13 days after 1 st dose	124/409	0.72 (0.54-0.95)	0.019	28.3 (5.3-45.7)	10/409	0.46 (0.24-0.90)	0.023	53.9 (10-76.3)
\geq 14 days after 1 st dose	218/591	0.66 (0.52-0.84)	0.001	34.1 (16.4-48.1)	15/591	0.41 (0.24-0.72)	0.002	58.6 (28.3-76.1)
0-13 days after 2 nd dose	50/232	0.39 (0.26-0.57)	< 0.0001	61.2 (42.6-73.7)	3/232	0.24 (0.07-0.77)	0.017	76 (22.9-92.5)
\geq 14 days after 2 nd dose	166/1048	0.29 (0.22-0.37)	< 0.0001	71.1 (62.9-77.6)	4/1046	0.13 (0.05-0.35)	< 0.0001	87.4 (65.1-95.4)
Age group: 18-49 years								
Unvaccinated	123/342			Ref	11/342			Ref
0-13 days after 1 st dose	53/255	0.66 (0.43-1.02)	0.062	33.7 (-2.1-56.9)	0/255	1	-	NA**
\geq 14 days after 1 st dose	65/275	0.67 (0.44-1.02)	0.064	32.6 (-2.3-55.6)	1/275	0.22 (0.02-2.05)	0.184	77.9 (-105.4-
								97.6)
0-13 days after 2 nd dose	16/118	0.33 (0.17-0.65)	0.001	66.9 (35-83.2)	1/118	0.30 (0.03-2.97)	0.303	70 (-196.5-97)
≥ 14 days after 2 nd dose	99/704	0.35 (0.23-0.52)	< 0.0001	65.1 (48-76.5)	2/704	0.45 (0.07-2.80)	0.390	55.3 (-180.2-
								92.9)
Age group: ≥50 years								
Unvaccinated	1809/2898			Ref	439/2898			Ref
0-13 days after 1 st dose	71/154	0.86 (0.58-1.27)	0.446	14.1 (-27.1-42)	10/154	0.65 (0.33-1.28)	0.213	34.9 (-28-66.9)
≥ 14 days after 1 st dose	153/316	0.67 (0.50-0.90)	0.009	32.9 (9.5-50.2)	14/316	0.45 (0.25-0.79)	0.005	55.2 (21.1-74.6)
0-13 days after 2 nd dose	34/114	0.44 (0.27-0.72)	0.001	55.9 (28-72.9)	2/114	0.20 (0.05-0.82)	0.025	80.2 (18.1-95.2)
≥ 14 days after 2 nd dose	67/342	0.21 (0.15-0.30)	< 0.0001	79 (69.7-85.5)	2/342	0.09 (0.02-0.37)	0.001	90.9 (62.6-97.8)

Abbreviations: OR, odds ratio; VE, vaccine effectiveness; CI, confidence interval

91 *Adjusted for age (as continuous), sex, presence of comorbidities and prior SARS-CoV-2 infection, week of testing, district of residence. OR is estimated using

92 multivariable regression model.

**The CI could not be estimated owing to zero/few events in the group.